PAVmed (PAVM) AI Stock Analysis

• Market Cap: $12.59M
• Dividend Yield: N/A
• Average Volume (3M): 179.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.71
• Revenue Growth: 22.15%
• EPS Growth: N/A
• Country: US
• Employees: 39
• Sector: Healthcare
• Sector Strength: 72
• Industry: Medical - Devices
• EPS (TTM): -2.25
• Shares Outstanding: 16,787,172
• 10 Day Avg. Volume: 154,623
• 30 Day Avg. Volume: 179,408
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.22
• Price to Cash Flow (P/CF): -0.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.00
• Price Target Upside: 455.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

PAVmed's overall score reflects significant financial challenges, including ongoing losses, high leverage, and negative cash flow, which are major concerns. While there is some positive momentum in technical indicators, the unattractive valuation, with a negative P/E ratio, further limits its appeal. The strategic transformations and growth in subsidiaries discussed in the earnings call are promising but do not offset the financial risks sufficiently.

Positive Factors

Commercialization and Growth

Lucid’s high growth and ramp up in commercialization will be a major catalyst for PAVmed’s stock.

Market Potential

PAVmed’s market potential in digital health and medtech, especially in cancer care, presents high rewards for the risks.

Valuation

PAVmed is considered significantly undervalued based on a sum-of-the-parts analysis, indicating potential upside.

Negative Factors

Price Target

Maintaining a BUY rating, but lowering the 12-month price target to $21 represents significant upside from the current share price.

Revenue Estimates

Revenue estimates for 2025 and 2026 have been lowered due to a slower expected ramp in patients.

PAVmed Business Overview & Revenue Model

Company Description

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

How the Company Makes Money

PAVmed generates revenue primarily through the commercialization and sale of its medical devices and technologies. The company earns income from product sales, licensing agreements, and potential partnerships with healthcare providers and distributors. PAVmed's business model focuses on advancing its pipeline of medical technologies to commercialization, thereby increasing its market presence and revenue streams. The company's earnings are influenced by factors such as product adoption rates, pricing strategies, regulatory approvals, and the expansion of its distribution networks. Strategic partnerships and collaborations in the healthcare industry also play a significant role in enhancing PAVmed's market reach and financial performance.

PAVmed Financial Statement Overview

Summary

PAVmed is facing significant financial challenges with ongoing losses, high leverage, and negative cash flows. While there is some revenue growth, the financials suggest sustainability concerns unless there is a turnaround in profitability and cash generation.

Income Statement

PAVmed has struggled with profitability, as indicated by consistently negative EBIT and net income figures over the years. The gross profit margin is negative due to high costs exceeding revenues. The company has shown some revenue growth, but the scale remains small, suggesting limited market penetration.

Balance Sheet

The balance sheet shows high leverage with a negative stockholders' equity indicating liabilities exceed assets, posing financial stability risks. The debt-to-equity ratio is unfavorable, and the equity ratio is negative, highlighting financial vulnerability.

Cash Flow

Cash flow is heavily negative, with significant operating cash outflows. The free cash flow remains negative, reflecting cash burn issues. Financing activities are a primary cash source, indicating reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.00B	2.45M	377.00K	500.00K	0.00
	Gross Profit
-1.84B	-3.97M	-3.24M	-85.00K	-23.00K
	EBIT
-44.49B	-68.80M	-90.93M	-54.39M	-23.35M
	EBITDA
-44.49B	-75.74M	-99.41M	-55.90M	-35.81M
	Net Income Common Stockholders
31.97B	-64.17M	-101.29M	-50.35M	-34.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.19B	19.64M	39.74M	77.26M	17.26M
	Total Assets
30.66B	33.12M	53.98M	86.98M	19.78M
	Total Debt
31.86M	48.73M	36.64M	0.00	14.96M
	Net Debt
30.68M	29.09M	-3.11M	-77.26M	-2.30M
	Total Liabilities
37.69B	57.14M	43.05M	7.56M	20.25M
	Stockholders Equity
-2.50B	-53.83M	-9.68M	61.67M	1.90M
Cash Flow		Free Cash Flow
-33.55B	-52.28M	-72.53M	-42.06M	-21.97M
	Operating Cash Flow
-33.55B	-52.04M	-70.98M	-40.59M	-21.91M
	Investing Cash Flow
-16.18B	758.00K	-4.74M	-3.72M	-55.00K
	Financing Cash Flow
31.28B	31.17M	38.21M	104.31M	33.01M

PAVmed Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAVM, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.70, and below the 200-day MA of 0.90, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 48.59 is Neutral, neither overbought nor oversold. The STOCH value of 37.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAVM.

PAVmed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
SNSE	45 Neutral	$12.78M	―	-58.40%	―	―	1.00%
BRTX	45 Neutral	$12.53M	―	-96.89%	―	175.03%	55.34%
SPRB	38 Underperform	$12.19M	―	-57.55%	―	-1.40%	35.83%
PAVM	33 Underperform	$12.59M	―	-499.57%	―	22.15%	―
TRAW	32 Underperform	$12.08M	―	-2255.45%	―	―	-487.26%

PAVmed Corporate Events

PAVmed Reports Record Revenue and Strategic Restructuring

PAVmed Inc., a diversified medical technology company, has made significant strides in solidifying its business with record quarterly revenue from Lucid’s EsoGuard tests and a strategic debt restructuring to maintain its Nasdaq listing. The company reported notable achievements, such as completing the clinical package for Medicare coverage submission and securing an NIH grant for Veris Health. Despite financial challenges, including a decrease in cash reserves, PAVmed continues to focus on growth and strategic partnerships, positioning itself for a promising future in the life sciences sector.